Objective: Japan Cancer of the Prostate Risk Assessment scores are reportedly useful for predicting progression-free survival after primary androgen deprivation therapy of prostate cancer patients. This study validated the risk assessment at a single institution. Methods: We studied 255 prostate cancer patients given primary androgen deprivation therapy. Progression-free survival, cause-specific survival and overall survival were analyzed according to Japan Cancer of the Prostate Risk Assessment score-based risk classification. Cases with lymph node or distant metastases were subdivided by the risk classification. Results: Ages ranged from 50 to 90 years (median: 76.5). Observation periods were 2-199 (median: 46.5) months. Primary androgen deprivation therapy includes combined androgen blockade in 150 cases (58.8%), uncombined luteinizing hormone-releasing hormone agonist in 97 (38.0%) and uncombined anti-androgenic agent in 8 (3.2%). Risk classified by Japan Cancer of the Prostate Risk Assessment scores was low in 104 cases (40.8%), intermediate in 86 (33.7%) and high in 65 (25.5%). The 5-year/10-year progression-free survival rates were 100%/80.8% in the low-risk, 82.3%/69.5% in the intermediate-risk and 34.7%/16.5% in the high-risk group. The 5-year/10-year cause-specific survival rates were 100%/100% in the low-risk, 90.7%/58.2% in the intermediate-risk and 63%/30.8% in the high-risk group. The 5-year/ 10-year overall survival rates were 87.5%/78.5% in the low-risk, 76.2%/43.1% in the intermediate-risk and 54.9%/25.4% in the high-risk group. For lymph node metastasis, cause-specific survival differed minimally between the intermediate-and high-risk groups (P = 0.1118). For distant metastasis, cause-specific survival differed significantly between the intermediate-and high-risk groups (P = 0.0264). Conclusions: Japan Cancer of the Prostate Risk Assessment score-based risk classification is useful for predicting post-primary androgen deprivation therapy progression-free survival, cause-specific survival and overall survival. Subtyping patients based on Japan Cancer of the Prostate Risk Assessment scores is particularly useful for predicting cause-specific survival with distant metastasis from prostate cancer.
Introduction
In Japan, androgen deprivation therapy (ADT) has been applied extensively as the primary treatment for prostate cancer, being used in cases ranging from confined to advanced prostate cancers. In advanced cases, the duration of ADT efficacy is generally 2-3 years (1), while in cases with confined prostate cancer this therapy may control the malignancy for a longer time (2) . For this reason, development of a risk assessment tool tailored to the circumstances in Japan, i.e. a tool which can cover all stages of the disease in patients receiving ADT as the primary therapy, is needed. Given this background, the Japan Study Group of Prostate Cancer (J-CaP) and the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) conducted research jointly and developed the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) for prognostic evaluation after PADT. The J-CAPRA score can reportedly serve as a useful tool for predicting progression-free survival (PFS) after primary androgen deprivation therapy (PADT) (3) .
PADT in Japan adopts not only combined androgen blockade (CAB) therapy but also uncombined luteinizing hormone-releasing hormone (LHRH) agonist therapy or uncombined anti-androgenic agent therapy, depending on the features of individual cases (4) . CAB therapy has been predominant as compared with other hormone therapies in Japan (4) , and the usefulness of the J-CAPRA score-based risk classification has been reported in patients administered CAB therapy (5) .
In Western countries, various risk assessment tools such as risk classification and nomograms (6) have been developed for use in the management of patients with prostate cancer. However, it has been suggested that the prognosis after ADT for prostate cancer differs, based on ethnicity, between Japanese and Western patients (7) . It is therefore desirable to develop a risk assessment tool tailored specifically to Japanese patients.
The present study aimed to examine the usefulness of the J-CAPRA score-based risk assessment for predicting outcomes after PADT with various drugs using data from a single facility.
Patients with lymph node metastasis or distant metastasis are generally considered to have poor prognosis. However, the prognosis varies among individual patients. Therefore, it was additionally designed to evaluate the usefulness of subdividing cases with lymph node metastasis or distant metastasis in accordance with the J-CAPRA scorebased risk classification.
Patients and methods

Patient population
Of the patients who had received PADT on the basis of a confirmed diagnosis of prostate cancer at the Osaka Medical Center for Cancer and Cardiovascular Diseases between January 1996 and December 2011, 255, in whom follow-up until progression of the disease or confirmation of the final outcome was possible, were enrolled in this study. Patients who underwent total prostatectomy or local radiotherapy for the prostate before disease progression were excluded. Clinical TNM classification was based on digital rectal examination, transrectal ultrasonography, computed tomography, magnetic resonance imaging and bone scintigraphy. The specimens obtained by prostate biopsy in all patients allowed diagnosis of prostate cancer (including Gleason grading) by multiple pathologists at our facility. ADT was administered in the form of CAB therapy (combined anti-androgenic agent + LHRH agonist therapy), uncombined LHRH agonist therapy or uncombined anti-androgenic agent therapy.
Assessment
Progression was defined as prostate specific antigen (PSA) elevation by at least 25% and a rise of 2 ng/ml or more from the PSA nadir. PFS, cause-specific survival (CSS) and overall survival (OS) were calculated as the duration from the first day of ADT until the day of confirmed progression or the day that the final PFS was confirmed, the day that death from cancer was confirmed, the day that non-cancer related death or final survival was confirmed or the day that death or final survival was confirmed.
Statistical analysis
J-CAPRA scores were calculated by the method described in a previous report (3) . On the basis of the J-CAPRA score, the risk was classified as low (0-2 points), intermediate (3-7 points) and high (8-12 points). PFS, CSS and OS were analyzed with univariate Cox proportional hazards regression models and the Kaplan-Meier method. The significance of the differences between each pair of J-CAPRA risk classes was tested employing the log-rank test. All statistical analyses were performed using JMP9 (SAS, Inc.). P < 0.05 was regarded statistically significant. The validation of J-CAPRA risk stratification was assessed by the c-index (8) . Its interpretation is similar to that of the area under a receiver operating curve for a diagnostic test: a c-index of 0.5 would indicate no improvement over random guess, whereas a c-index of 1.0 would indicate perfect predictive accuracy (8) . The c-indexes were calculated using R version3.1.1 (Foundation for Statistical Computing, Vienna, Austria).
Results
The median follow-up period was 46.5 months (range 2-199 months). The median age at the start of treatment was 76.5 years (range 50-90 years). PADT consisted of CAB therapy in 150 cases (58.8%), uncombined LHRH agonist therapy in 97 (38.0%), and uncombined anti-androgenic agent therapy in 8 (3.2%). summarizes the background variables and J-CAPRA score of patients enrolled in this study. Gleason scores were 8 or higher in 127 cases (49.8%). PSA levels are >20 ng/ml in 144 cases (56.5%). In 68 cases (26.7%), T stage was T3b or T4. In 57 cases (22.4%), lymph node metastasis was regarded as positive when confirmed by diagnostic imaging at the time of diagnosis. In 80 cases (31.4%), distant metastasis was found by diagnostic imaging at the time of diagnosis. The median J-CAPRA score was 3. The J-CAPRA risk for disease progression was low in 104 cases (40.8%), intermediate in 86 (33.7%) and high in 65 (25.5%).
Biochemical progression was noted in two cases (1.9%) from the low-risk group, 13 (15.1%) from the intermediate-risk group and 42 (64.6%) from the high-risk group. The numbers of deaths (deaths from prostate cancer/deaths from other causes) were 0/12 in the lowrisk group, 9/11 in the intermediate-risk group and 29/6 in the highrisk group. Of the 57 patients positive for lymph node metastasis, 42 (73.7%) were high-risk cases. Of the 80 patients positive for distant metastasis, 62 (77.5%) were high-risk cases. Figure 1 graphically To test the value of J-CAPRA score risk classification for predicting the prognosis of advanced disease, cases with lymph node metastasis or distant metastasis were analyzed for CSS. Since lymph node metastasis and distant metastasis are included in five J-CAPRA assessment factors, the remaining four factors were additively taken into account in each analysis. Figure 2 illustrates the Kaplan-Meier curves for CSS when lymph node metastasis positive cases and distant metastasis positive cases were subdivided into intermediate-and high-risk groups. Among patients positive for lymph node metastasis, CSS did not differ significantly between the intermediate-and high-risk groups (P = 0.1118). However, among patients positive for distant metastasis, CSS differed significantly between these two groups (P = 0.0264).
Discussion
ADT plays a central role in primary drug therapy for patients with advanced prostate cancer and elderly patients with confined prostate cancer. The survival-extending effect of ADT in patients with Stage III/IV prostate cancer has been demonstrated (9) , and there is a report describing prolonged survival, comparable to that of the population in general, having also been achieved by ADT in patients with Stage II/III confined prostate cancer (10) . However, prior to the J-CAPRA score being proposed, there was no prognostic assessment tool applicable to post-ADT patients with various stages of prostate cancer.
In the present study, risk classification on the basis of J-CAPRA scores was confirmed to be useful for predicting the outcomes of patients with various stages of prostate cancer as well as in those who had received ADT using various drugs (not confined to CAB therapy). The results obtained in this study suggest that this risk assessment tool may allow not only prediction of outcomes after ADT but also appropriate modification of ADT tailored to the risk classes of individual cases. In the present study, the group of patients rated at being at low risk on the basis of J-CAPRA scores had an OS of 78.8% at 10 years and CSS of 100% at 10 years. Considering the reports that prolonged ADT can cause bone mineral content reduction (11), increased fracture risk (12) and elevated insulin resistance (13) , it may be rational to select intermittent ADT for the low-risk group from the viewpoint of reducing these adverse reactions (14) .
In the high-risk group, on the other hand, PFS at 5-years/10-years were 34.7%/16.5%, suggesting a high likelihood for the development of resistance to ADT over time. Patients with lymph node or distant metastasis were often rated as being at high risk, but the outcomes of the intermediate-risk group were significantly better even for patients with distant metastasis. In these patients, favorable factors in terms of Gleason score, clinical T stage, PSA and lymph node metastasis were considered to have beneficial effects on ADT. Therefore, when dealing with patients who have distant metastasis, it is advisable to consider the application of therapies other than ADT (e.g. radiotherapy and combined use of drugs for bone disease treatment or novel targeted agent) depending on the risk class, instead of administering ADT alone.
Limitations of the present study include retrospective analysis and small sample size, especially for subtyping patients with metastasis. However, the usefulness of the J-CAPRA score for predicting PFS, CSS and OS after PADT was demonstrated employing data from a single facility. Use of this convenient tool is expected to facilitate establishment of an optimum ADT strategy for prostate cancer.
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